ES2090317T3 - Uso del acido 3-guanidinopropionico en la fabricacion de un medicamento para el tratamiento y prevencion del exceso de adiposidad. - Google Patents

Uso del acido 3-guanidinopropionico en la fabricacion de un medicamento para el tratamiento y prevencion del exceso de adiposidad.

Info

Publication number
ES2090317T3
ES2090317T3 ES91905921T ES91905921T ES2090317T3 ES 2090317 T3 ES2090317 T3 ES 2090317T3 ES 91905921 T ES91905921 T ES 91905921T ES 91905921 T ES91905921 T ES 91905921T ES 2090317 T3 ES2090317 T3 ES 2090317T3
Authority
ES
Spain
Prior art keywords
acid
guanidinopropionico
prevention
manufacture
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91905921T
Other languages
English (en)
Inventor
Martin Durham Meglasson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ES2090317T3 publication Critical patent/ES2090317T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Fodder In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SUMINISTRA UN METODO PARA EL TRATAMIENTO O PREVENCION DE CIERTOS DESORDENES METABOLICOS QUE COMPRENDEN LA ADMINISTRACION DE ACIDO 3 GPA). ESTOS DESORDENES METABOLICOS DEL METABOLISMO HUMANO Y ANIMAL, POR EJEMPLO LA HIPERGLICEMIA, LA TOLERANCIA DESEQUILIBRADA A LA GLUCOSA, LA HIPERINSULINEMIA Y LA INSENSIBILIDAD A LA INSULINA, LA HIPERAMILINEMIA, LA ADIPOSIDAD EXCESIVA, Y LA HIPERLIPIDEMIA, PUEDEN PRESENTARSE EN LOS SIGUIENTES ESTADOS DE ENFERMEDAD: LA DIABETES NO DEPENDIENTE DE LA INSULINA (NIDDM), LA OBESIDAD, LA HIPERTENSION Y LA ARTERIOSCLEROSIS. EL 3 PUEDE ADMINISTRARSE MEZCLADO EN LA DIETA DE LOS ANIMALES DOMESTICOS O COMO PREPARACION FARMACEUTICA TAL COMO TABLETAS ORALES O CAPSULAS, MEDIANTE INYECCION O MEDIANTE DISPOSITIVOS IMPLANTABLES DE LIBERACION SOSTENIDA INCREMENTANDO EL CONTENIDO DE PROTEINAS DEL CUERPO MIENTRAS DECRECE SU CONTENIDO GRASO. ELLO DARIA COMO RESULTADO UN TEJIDO MUSCULAR CON MENOS GRASA.
ES91905921T 1990-02-28 1991-02-27 Uso del acido 3-guanidinopropionico en la fabricacion de un medicamento para el tratamiento y prevencion del exceso de adiposidad. Expired - Lifetime ES2090317T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48661590A 1990-02-28 1990-02-28
PCT/US1991/000334 WO1991012799A1 (en) 1990-02-28 1991-01-22 Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders

Publications (1)

Publication Number Publication Date
ES2090317T3 true ES2090317T3 (es) 1996-10-16

Family

ID=26782896

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91905921T Expired - Lifetime ES2090317T3 (es) 1990-02-28 1991-02-27 Uso del acido 3-guanidinopropionico en la fabricacion de un medicamento para el tratamiento y prevencion del exceso de adiposidad.

Country Status (14)

Country Link
US (2) US5132324A (es)
EP (2) EP0713699A2 (es)
JP (2) JPH0825875B2 (es)
KR (1) KR100190257B1 (es)
AT (1) ATE141505T1 (es)
AU (2) AU7316591A (es)
CA (1) CA2073873C (es)
DE (1) DE69121561T2 (es)
DK (1) DK0517820T3 (es)
ES (1) ES2090317T3 (es)
GR (1) GR3021424T3 (es)
NZ (2) NZ245541A (es)
WO (2) WO1991012799A1 (es)
ZA (1) ZA911496B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
US6008253A (en) * 1991-08-26 1999-12-28 The Upjohn Company Use of 3-guanidinopropionic acid to increase endurance, stamina and exercise capacity in a mammal
JPH06510286A (ja) * 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー ３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
EP0600973A1 (en) * 1991-08-27 1994-06-15 The Upjohn Company A method for treatment of metabolic disorders and metabolism
WO1994026261A1 (en) * 1993-05-14 1994-11-24 Amira, Inc. Treating body parts susceptible to ischemia using creatine analogs
US5808246A (en) * 1995-09-25 1998-09-15 Otis Elevator Company Triac drive for three-phase line-powered linear induction motor elevator door operator
CA2231632C (en) * 1995-10-11 2004-01-20 Avicena Group, Inc. Use of creatine analogues for the treatment of disorders of glucose metabolism
PL327471A1 (en) * 1995-12-22 1998-12-07 Smithkline Beecham Plc Aminoguanidines for trweating niddm
DE19622222A1 (de) * 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
US20040122096A1 (en) * 1996-06-03 2004-06-24 Hoechst Aktiengesellschaft Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids
AU1725197A (en) * 1997-02-13 1998-09-08 Smithkline Beecham Plc Use of nitric oxid synthase inhibitors for the treatment of diabetes
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
CA2339879C (en) 1998-08-24 2011-11-15 Toshio Miyata Carbonyl-stress improving agent and peritoneal dialysate
US7014307B2 (en) * 1998-11-09 2006-03-21 Silverbrook Research Pty Ltd Printing unit for an image recordal and generation apparatus
US20050027005A1 (en) * 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
US7670849B2 (en) * 2005-04-29 2010-03-02 Henkin Robert I Method for diagnosing insulin resistance from nasal secretions
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
JP4777225B2 (ja) * 2006-12-04 2011-09-21 キヤノン株式会社 吐出用液体及び吐出方法
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
WO2012138214A1 (en) * 2011-04-08 2012-10-11 Brewster Lizzy Maritza Beta-guanidinopropionic acid for the treatment of hypertension
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
CN105963250A (zh) * 2016-06-21 2016-09-28 俞力 一种口服葡萄糖溶液及其制备方法
JP2023505687A (ja) * 2019-12-11 2023-02-10 インスピルナ，インコーポレーテッド 癌の処置方法
CN115485027A (zh) 2020-03-24 2022-12-16 思瑞诺医疗有限公司 冠状病毒感染引起的化学感觉功能障碍的治疗
KR102615692B1 (ko) * 2021-10-13 2023-12-19 주식회사 휴엔켐 베타-구아니디노프로피온산을 포함하는 간섬유화 예방 또는 치료용 조성물
KR102822799B1 (ko) 2022-11-09 2025-06-20 충남대학교산학협력단 베타-구아니디노프로피온산을 포함하는 장내 미생물 개선용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA891509A (en) * 1972-01-25 Beecham Group Limited Esters and amides of guanidine aliphatic acids
GB1153424A (en) * 1965-04-15 1969-05-29 Horlicks Ltd Pharmaceutical Compositions
GB1195199A (en) * 1966-11-25 1970-06-17 Horlicks Pharmaceuticals Ltd Improvements in Compositions comprising Insulin.
GB1195200A (en) * 1967-02-07 1970-06-17 Horlicks Pharmaceuticals Ltd Pharmaceutical Compositions.
US3843798A (en) * 1973-03-12 1974-10-22 Stanley Drug Products Inc Methods and compositions for inducing resistance to bacterial infections
GB1552179A (en) * 1976-11-02 1979-09-12 Beecham Group Ltd Pharmaceutical compositions for treating hyperglycaemia
JPH06510286A (ja) * 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー ３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物

Also Published As

Publication number Publication date
WO1991012800A1 (en) 1991-09-05
CA2073873C (en) 1996-10-29
EP0713699A3 (es) 1996-07-10
GR3021424T3 (en) 1997-01-31
AU645076B2 (en) 1994-01-06
US5134164A (en) 1992-07-28
DE69121561T2 (de) 1997-01-30
EP0517820A1 (en) 1992-12-16
AU7485091A (en) 1991-09-18
KR100190257B1 (ko) 1999-06-01
DK0517820T3 (da) 1997-06-09
JP2637712B2 (ja) 1997-08-06
JPH05505189A (ja) 1993-08-05
NZ245541A (en) 1997-05-26
CA2073873A1 (en) 1991-08-29
ZA911496B (en) 1991-12-24
WO1991012799A1 (en) 1991-09-05
DE69121561D1 (de) 1996-09-26
JPH0825875B2 (ja) 1996-03-13
AU7316591A (en) 1991-09-18
EP0517820B1 (en) 1996-08-21
JPH0820534A (ja) 1996-01-23
US5132324A (en) 1992-07-21
EP0713699A2 (en) 1996-05-29
NZ237249A (en) 1994-09-27
ATE141505T1 (de) 1996-09-15

Similar Documents

Publication Publication Date Title
GR3021424T3 (en) Use of 3-guanidinopropionic acid in the manufacture of a medicament for the treatment and prevention of excess adiposity
US5091171B1 (en) Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
ES2160124T3 (es) Utilizacion de bcl-2 para la fabricacion de medicamentos para el tratamiento terapeutico y la prevencion de enfermedades.
ES2061989T3 (es) Uso de esteres alquilicos del acido piroglutamico para la fabricacion de un medicamento para el tratamiento de la ictiosis.
ES2096577T3 (es) Utilizacion del cetoconazol y un retinoide para el tratamiento del acne vulgar.
DE3687099D1 (de) Verwendung von einem cartilago-induzierenden faktor (cif) zur herstellung eines arzneimittels zur behandlung von entzuendungen.
ES2173111T3 (es) Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
EP1023905A3 (en) Pharmaceutical composition containing S-nitroso-immunoglobulins and use thereof
NZ219374A (en) Topical pharmaceutical containing tamoxifen
EP0285856A3 (en) Use of dihydroergotamine and its salts in the local treatment of trophic disorders
ES2181702T3 (es) Derivados de melatonina para su uso en el tratamiento de enfermedad es del sueño.
ZA898554B (en) Liquid oral formulation
DE69206621D1 (de) Sprühspender für die verabreichung von gesprühten arzneimitteln in die nase.
MX9203208A (es) Composicion farmaceutica y metodo para el tratamiento de trastornos digestivos.
IT1264428B1 (it) Composizioni farmaceutiche per il trattamento della psoriasi
BG95724A (en) Medicaments with analgetic, antiphlogestic and antibacterial effect for external use

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 517820

Country of ref document: ES

FG2A Definitive protection

Ref document number: 517820

Country of ref document: ES